Strategies for treating aspergillosis due to azole-resistant Aspergillus fumigatus: From the bench to the bedside.
In case you object to the disclosure of your thesis, you can contact firstname.lastname@example.org
[S.l. : s.n.]
Radboud Universiteit Nijmegen, 25 april 2014
Promotores : Verweij, P.E., Mouton †, J.W. Co-promotores : Melchers, W.J.G., Bruggemann, R.J.M.
Display more detailsDisplay less details
SubjectRadboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences
In humans, Aspergillus fumigatus is the most common and life-threatening aerial fungal pathogen, especially among immunocompromised patients, with an overall mortality ranging between 30 to 88%. Azole antifungals, such as voriconazole and posaconazole, are recommended first choice drugs to manage aspergillus diseases. However, acquired azole-resistance in A.fumigatus is an emerging problem that compromises the clinical efficacy of azole antifungals. Although azole resistance may emerge during antifungal therapy of individual azole-treated patients, selection of resistance may also occur in the environment. Given the prominent role of azoles in the management of aspergillus diseases, successful management of azole-resistant Aspergillus diseases in patients with chronic pulmonary aspergillosis (CPA) and invasive aspergillosis (IA) is a challenge. Therefore, it is important to explore alternative therapeutic approaches. The research described in this thesis is aimed to provide some experimental evidence that will help to guide physicians in the treatment of patients with azole-resistant aspergillus diseases.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.